- Home
- ATHA
ATHA
Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 14.8M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 47.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $8.26 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Athira Pharma Inc. News
ATHA Breaking Stock News: Dive into ATHA Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 months ago
This Athira Pharma Insider Increased Their Holding By 111% Last Year
TipRanks
5 months ago
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105
GlobeNewswire
5 months ago
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
GlobeNewswire
5 months ago
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
GlobeNewswire
7 months ago
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
MT Newswires
7 months ago
Terns Pharmaceuticals Names Andrew Gengos as Chief Financial Officer
Simply Wall St.
8 months ago
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth?
Simply Wall St.
10 months ago
Athira Pharma Insider Ups Holding By 111% During Year
Compare ATHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHA Athira Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.